Document Type : Original Article(s)


1 Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

2 Department of Basic Oncology, Ege University, Institute of Health Sciences, Izmir, Turkey

3 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran


Background: Long noncoding RNA (lncRNA) is recognized as an essential controller of gene expression and other activities of the cells. Additionally, lncRNAs have a critical role in the progression and growth of human malignancies, like melanoma. Among lncRNAs, thymopoietin (TMPO)-antisense RNA 1 (TMPO AS- 1) has a significant role in melanoma. The current study aimed to determine the expression level of TMPO AS-1 in melanoma patients.
Method: In this case-control research, 50 pairs of tumor and non-tumor tissues of melanoma patients were separated by the surgeon. Subsequently, TMPO AS-1 expression level in the tissues was evaluated. We used TRIzol to extract total RNA from the tumor and non-tumor tissues, following which complementary DNA was synthesized. The TMPO AS-1 expression level of TMPO AS-1 was evaluated via quantitative reverse transcription- polymerase chain reaction (qRT-PCR) technique. Moreover, clinicopathological features of the melanoma patients were evaluated.
Results: Our findings revealed that TMPO AS-1 expression level was upregulated in the melanoma tissues in comparison with the non-tumor ones. Remarkably, the TMPO AS-1 expression level was considerably correlated to the clinicopathological characteristics of the patients, including lymph nodes and distant metastasis.
Conclusion: Upregulation of TMPO AS-1 in melanoma indicated that TMPO AS- 1 and its downstream signal pathways could be used as a new target treatment option and prognostic tumor marker for melanoma.


Habib Zarredar (Google Scholar)
Shahram Ghasembaglou (PubMed)


How to cite this article:

Zarredar H, Asadi M, Shanehbandi D, Zafari V, Bornodeli S, Soleimani Z, et al. Evaluation of the LncRNA TMPO AS-1 expression level in melanoma tissues in comparison to paired normal marginal tissues. Middle East J Cancer. 2023;14(3):399-404. doi: 10.30476/mejc.2022. 94761.1744.

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. doi: 10.3322/caac.21660.
  2. Bailar JC 3rd, Gornik HL. Cancer undefeated. N Engl J Med. 1997;336(22):1569-74. doi: 10.1056/NEJM199705293362206.
  3. Zarredar H, Pashapour S, Farajnia S, Ansarin K, Baradaran B, Ahmadzadeh V, et al. Targeting the KRAS, p38α, and NF-κB in lung adenocarcinoma cancer cells: The effect of combining RNA interferences with a chemical inhibitor. J Cell Biochem. 2019;120(6):10670-7. doi: 10.1002/jcb.28357.
  4. Domingues B, Lopes JM, Soares P, Pópulo H. Melanoma treatment in review. Immunotargets Ther. 2018;7:35-49. doi: 10.2147/ITT.S134842.
  5. Handjani F, Saki N, Parhizgar A, Kardeh S, Rafiee S, Yaghutian Nezhad L,et al. Epidemiology of malignant melanoma over a thirty-two year period (1981-2013) in southern Iran. Middle East J Cancer. 2016;7(4):199-202.
  6. Ghanadan A, Ehsani A, Farahmand A, Mirzaei M. Tumor infiltrating lymphocytes in different stages of malignant melanoma and correlation with tumor stage and other prognostic factors: a retrospective multicenter study. Middle East J Cancer. 2017;8(4): 207-12.
  7. Erdei E, Torres SM. A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther. 2010;10(11):1811-23. doi: 10.1586/era.10.170.
  8. Aftabi Y, Ansarin K, Shanehbandi D, Khalili M, Seyedrezazadeh E, Rahbarnia L, et al. Long non-coding RNAs as potential biomarkers in the prognosis and diagnosis of lung cancer: A review and target analysis. IUBMB Life. 2021;73(2):307-27. doi: 10.1002/iub.2430.
  9. Zhao L, Li Y, Song A. Inhibition of lncRNA TMPO‑AS1 suppresses proliferation, migration and invasion of colorectal cancer cells by targeting miR‑143‑3p. Mol Med Rep. 2020;22(4):3245-54. doi: 10.3892/mmr.2020.11427.
  10. Daryabari SS, Safaralizadeh R, Hosseinpourfeizi M, Moaddab Y, Shokouhi B. Overexpression of SSH1 in gastric adenocarcinoma and its correlation with clinicopathological features. J Gastrointest Oncol. 2018;9(4):728-33. doi: 10.21037/jgo.2018.03.09.
  11. Zarredar H, Farajnia S, Ansarin K, Baradaran B, Aria M, Asadi M. Synergistic effect of novel EGFR inhibitor AZD8931 and p38α siRNA in lung adenocarcinoma cancer cells. Anticancer Agents Med Chem. 2019;19(5):638-44. doi: 10.2174/1871520619666190301125203.
  12. Dong HT, Liu Q, Zhao T, Yao F, Xu Y, Chen B, et al. Long non-coding RNA LOXL1-AS1 drives breast cancer invasion and metastasis by antagonizing miR-708-5p expression and activity. Mol Ther Nucleic Acids. 2020;19:696-705. doi: 10.1016/j.omtn.2019.12.016.
  13. Malikhan H, Siasi Torbati E, Majd A, Gheibi N. Anti-cancer properties of nicotinic Cid-alpha linolenic acid derivative on A375 melanoma cell line: Assessment of apoptosis and WNT signaling pathways. Middle East J Cancer. 2021: 13(4):593-606. doi: 10.30476/MEJC.2021.89494.1530.
  14. Qin Z, Zheng X, Fang Y. Long noncoding RNA TMPO-AS1 promotes progression of non-small cell lung cancer through regulating its natural antisense transcript TMPO. Biochem Biophys Res Commun. 2019;516(2):486-93. doi: 10.1016/j.bbrc.2019.06.088.
  15. Liu X, Wang H, Tao GL, Chu TB, Wang YX, Liu L. LncRNA-TMPO-AS1 promotes apoptosis of osteosarcoma cells by targeting miR-329 and regulating E2F1. Eur Rev Med Pharmacol Sci. 2020;24(21):11006-15. doi: 10.26355/eurrev_202011_23585.
  16. Peng X, Yan J, Cheng F. LncRNA TMPO-AS1 up-regulates the expression of HIF-1α and promotes the malignant phenotypes of retinoblastoma cells via sponging miR-199a-5p. Pathol Res Pract. 2020;216(4):152853. doi: 10.1016/j.prp.2020.152853.
  17. Zhao H, Ding F, Zheng G. LncRNA TMPO-AS1 promotes LCN2 transcriptional activity and exerts oncogenic functions in ovarian cancer. FASEB J. 2020;34(9):11382-94. doi: 10.1096/fj.201902683R.
  18. Wang Y, Ma J, Li R, Gao X, Wang H, Jiang G. LncRNA TMPO-AS1 serves as a sponge for miR-4731-5p modulating breast cancer progression through FOXM1. Am J Transl Res. 2021;13(10):11094-6.
  19. Li Z, Feng Y, Zhang Z, Cao X, Lu X. TMPO-AS1 promotes cell proliferation of thyroid cancer via sponging miR-498 to modulate TMPO. Cancer Cell Int. 2020;20:294. doi: 10.1186/s12935-020-01334-4.
  20. Mitobe Y, Ikeda K, Suzuki T, Takagi K, Kawabata H, Horie-Inoue K, et al. ESR1-stabilizing long noncoding RNA TMPO-AS1 promotes hormone-refractory breast cancer progression. Mol Cell Biol. 2019;39(23):e00261-19. doi: 10.1128/MCB.00261-19.
  21.  Zhang L, Zhang Y, Zhang C, Hou Y, Tian F. TMPO-AS1 is an independent prognostic factor for patients with laryngeal squamous cell carcinoma. Rev Assoc Med Bras (1992). 2020;66(6):784-8. doi: 10.1590/1806-9282.66.6.784.